ES2100459T3 - Derivados de n-isoxazol-fenilsulfonamidas y su uso como antagonistas de la endotelina. - Google Patents

Derivados de n-isoxazol-fenilsulfonamidas y su uso como antagonistas de la endotelina.

Info

Publication number
ES2100459T3
ES2100459T3 ES93303373T ES93303373T ES2100459T3 ES 2100459 T3 ES2100459 T3 ES 2100459T3 ES 93303373 T ES93303373 T ES 93303373T ES 93303373 T ES93303373 T ES 93303373T ES 2100459 T3 ES2100459 T3 ES 2100459T3
Authority
ES
Spain
Prior art keywords
fenilsulfonamidas
endotheline
isoxazol
antagonists
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93303373T
Other languages
English (en)
Inventor
Natesan Murugesan
John T Hunt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
ER Squibb and Sons LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ER Squibb and Sons LLC filed Critical ER Squibb and Sons LLC
Application granted granted Critical
Publication of ES2100459T3 publication Critical patent/ES2100459T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C07D261/16—Benzene-sulfonamido isoxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE PRESENTAN COMPUESTOS DE LA FORMULA (I) QUE INHIBEN LA ACTIVIDAD DE LA ENDOTELINA. LOS SIMBOLOS SE DEFINEN COMO SIGUEN: UNA DE ENTRE X E Y ES N Y LA OTRA ES O; R1, R2 Y R3 SON CADA UNA INDEPENDIENTEMENTE A) HIDROGENO, EXCEPTO QUE R1 SEA DIFERENTE DEL HIDROGENO; B) ALQUIL, ALQUENIL, ALQUINIL, ALCOXIDO, CICLOALQUIL, CICLOALQUILALQUIL, CICLOALQUENIL, CICLOALQUENILALQUIL, ARIL, ARILOXIDO, ARALQUIL O ARALCOXIDO, CUALQUIERA DE LOS CUALES PUESE ESTAR SUSTITUIDO CON Z1, Z2 Y Z3; C) HALO; D) HIDROXIL; E) CIANO; F) NITRO; G) -C(O)H O -C(O)R6-; H) -COH O -CO2R6; I) -SH, -S(O)NR6, -S(O)M-OR6, O-S(O)MOH, O -O-S(O)M-OR6; J) -Z4-NR7R8; O K) -Z4-N(R11)-Z5-NR9R10; Y LOS SIMBOLOS RESTANTES SON SEGUN SE DEFINEN EN LAS ESPECIFICACIONES.
ES93303373T 1992-05-06 1993-04-29 Derivados de n-isoxazol-fenilsulfonamidas y su uso como antagonistas de la endotelina. Expired - Lifetime ES2100459T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87900092A 1992-05-06 1992-05-06

Publications (1)

Publication Number Publication Date
ES2100459T3 true ES2100459T3 (es) 1997-06-16

Family

ID=25373236

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93303373T Expired - Lifetime ES2100459T3 (es) 1992-05-06 1993-04-29 Derivados de n-isoxazol-fenilsulfonamidas y su uso como antagonistas de la endotelina.

Country Status (22)

Country Link
EP (1) EP0569193B1 (es)
JP (1) JP3286391B2 (es)
KR (1) KR100277454B1 (es)
CN (1) CN1066441C (es)
AT (1) ATE149155T1 (es)
AU (1) AU659545B2 (es)
CA (1) CA2095174A1 (es)
CY (1) CY2016A (es)
DE (1) DE69308229T2 (es)
DK (1) DK0569193T3 (es)
ES (1) ES2100459T3 (es)
FI (1) FI112655B (es)
GR (1) GR3023421T3 (es)
HK (1) HK98197A (es)
HU (1) HU218938B (es)
IL (1) IL105481A (es)
MX (1) MX9302618A (es)
NO (1) NO303065B1 (es)
NZ (1) NZ247440A (es)
PL (1) PL178165B1 (es)
RU (1) RU2133742C1 (es)
ZA (1) ZA932914B (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124343A (en) * 1919-01-27 2000-09-26 Rhone-Poulenc Rorer Limited Substituted phenyl compounds with a substituent having a thienyl ring
CN88101343A (zh) * 1987-02-09 1988-09-14 三井石油化学工业株式会社 片状成型材料和以其为一层的层压制品
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5594021A (en) * 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US5736509A (en) * 1990-12-14 1998-04-07 Texas Biotechnology Corporation Cyclic peptide surface feature mimics of endothelin
US5767310A (en) * 1993-03-19 1998-06-16 Merck & Co., Inc. Phenoxyphenylacetic acid derivatives
FI941826A (fi) 1993-04-21 1994-10-22 Takeda Chemical Industries Ltd Menetelmät ja koostumukset elimen hypofunktion ennaltaehkäisemiseksi ja/tai terapeuttiseksi hoitamiseksi
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US6376523B1 (en) 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6541498B2 (en) 1993-05-20 2003-04-01 Texas Biotechnology Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6030991A (en) * 1993-05-20 2000-02-29 Texas Biotechnology Corp. Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US5686478A (en) * 1993-07-20 1997-11-11 Merck & Co. Inc. Endothelin antagonists
ES2081250B1 (es) * 1993-07-28 1996-10-16 Squibb & Sons Inc Antagonistas de endotelina a base de fenilsulfonamida.
US5965732A (en) * 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
CA2173875A1 (en) * 1993-11-01 1995-05-11 Hideyuki Saika Endothelin receptor antagonists
US5431842A (en) * 1993-11-05 1995-07-11 The Procter & Gamble Company Liquid detergents with ortho-substituted phenylboronic acids for inhibition of proteolytic enzyme
IL111959A (en) * 1993-12-17 2000-07-16 Tanabe Seiyaku Co N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
GB9409618D0 (en) * 1994-05-13 1994-07-06 Zeneca Ltd Pyridine derivatives
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5559135A (en) * 1994-09-14 1996-09-24 Merck & Co., Inc. Endothelin antagonists bearing pyridyl amides
US5538991A (en) * 1994-09-14 1996-07-23 Merck & Co., Inc. Endothelin antagonists bearing 5-membered heterocyclic amides
FR2724654B1 (fr) * 1994-09-16 1997-12-12 Roussel Uclaf Nouveaux derives de l'acide gallique, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
FR2725988B1 (fr) * 1994-10-24 1997-01-24 Roussel Uclaf Nouveaux derives de pyrazolones et pyrazoles acides, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
CN1136192C (zh) * 1994-12-20 2004-01-28 弗·哈夫曼-拉罗切有限公司 芳基和杂芳基-氨磺酰衍生物,它们的制备及其作为内皮素拮抗剂的用途
IL116916A (en) * 1995-02-06 2000-09-28 Bristol Myers Squibb Co Substituted biphenyl sulfonamide derivatives and pharmaceutical compositions containing the same
DE19509950A1 (de) * 1995-03-18 1996-09-19 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
AU711968B2 (en) * 1995-04-04 1999-10-28 Encysive Pharmaceuticals Inc. Thienyl-, furyl-, pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5739333A (en) * 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
UA58494C2 (uk) 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
GB9512697D0 (en) * 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
AU7094996A (en) * 1995-09-26 1997-04-17 Shionogi & Co., Ltd. Novel sulfonamide compounds and medicinal composition
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
DE19540737A1 (de) 1995-11-02 1997-05-07 Bayer Ag Substituierte Sulfonylamino(thio)carbonylverbindungen
US5977117A (en) * 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
WO1997029747A1 (en) * 1996-02-20 1997-08-21 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US5958905A (en) * 1996-03-26 1999-09-28 Texas Biotechnology Corporation Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
US5804585A (en) * 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
US5877193A (en) * 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
AU6187898A (en) * 1997-01-30 1998-08-25 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
ID25921A (id) 1997-04-28 2000-11-09 Texas Biotechnology Corp Sulfonamida-sulfonamida untuk pengobatan penyakit-penyakit yang dimediakan endotelin
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
MXPA01009362A (es) 1999-03-19 2002-06-04 Squibb Bristol Myers Co Metodos para la preparacion de bifenil isoxazol sulfonamidas.
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
DE60030764T2 (de) * 1999-12-15 2007-09-13 Bristol-Myers Squibb Co. Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten
MXPA02006461A (es) * 1999-12-31 2003-09-05 Texas Biotechnology Corp Sulfonamidas y derivados de las mismas que modulan la actividad de endotelina.
CA2348847A1 (en) * 2000-05-31 2001-11-30 Pfizer Inc. New isoxazole-sulfonamide endothelin antagonists
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
WO2006046916A1 (en) * 2004-10-29 2006-05-04 Astrazeneca Ab Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases
US8541592B2 (en) 2005-11-22 2013-09-24 Amgen Inc. Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1
CA2659155A1 (en) 2006-07-20 2008-01-24 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11.beta.-hsd-1
TW200829578A (en) 2006-11-23 2008-07-16 Astrazeneca Ab Chemical compounds 537
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
UY31832A (es) 2008-05-20 2010-01-05 Astrazeneca Ab Derivados de indazol sustituidos con fenilo y benzodioxinilo
NZ593473A (en) 2009-01-12 2013-02-22 Pfizer Ltd Sulfonamide derivatives
CA2804173C (en) 2010-07-09 2015-01-13 Pfizer Limited Sulfonamide nav1.7 inhibitors
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
GB201721185D0 (en) 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
CN114761383A (zh) * 2019-06-12 2022-07-15 诺瑟拉有限公司 磺酰胺衍生物及其用途
WO2020249667A1 (en) 2019-06-12 2020-12-17 NodThera Limited Sulfonylurea derivatives and uses thereof
JP7352662B2 (ja) 2019-06-18 2023-09-28 ファイザー・インク ベンゾイソオキサゾールスルホンアミド誘導体
BR112023019460A2 (pt) * 2021-06-22 2024-01-23 Alchemedicine Inc Composto, antagonista do receptor de endotelina a e composição farmacêutica que compreendem o mesmo e usos do composto como terapia e na produção de um antagonista do receptor de endotelina a
WO2024101440A1 (ja) * 2022-11-11 2024-05-16 株式会社アークメディスン 化合物、エンドセリンａ受容体拮抗剤、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3300488A (en) * 1963-12-23 1967-01-24 Shionogi & Co Nu, nu'-bis [4-halogenated-5-alkyl-3-isoxazolylsulfamoyl)-phenyl]-ureas
US4732519A (en) * 1986-12-24 1988-03-22 Illinois Tool Works Inc. Fastener assembly with axial play
TW270116B (es) * 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US5305312A (en) * 1992-02-07 1994-04-19 At&T Bell Laboratories Apparatus for interfacing analog telephones and digital data terminals to an ISDN line
TW224462B (es) * 1992-02-24 1994-06-01 Squibb & Sons Inc

Also Published As

Publication number Publication date
HU9301305D0 (en) 1993-09-28
FI932052A0 (fi) 1993-05-06
ATE149155T1 (de) 1997-03-15
FI112655B (fi) 2003-12-31
EP0569193B1 (en) 1997-02-26
NZ247440A (en) 1995-04-27
KR930023337A (ko) 1993-12-18
DK0569193T3 (es) 1997-03-17
HUT65751A (en) 1994-07-28
MX9302618A (es) 1994-05-31
CN1084515A (zh) 1994-03-30
JPH0649046A (ja) 1994-02-22
CA2095174A1 (en) 1993-11-07
CN1066441C (zh) 2001-05-30
IL105481A (en) 1996-12-05
EP0569193A1 (en) 1993-11-10
DE69308229D1 (de) 1997-04-03
CY2016A (en) 1998-02-20
AU3838293A (en) 1993-11-11
PL178165B1 (pl) 2000-03-31
FI932052A (fi) 1993-11-07
RU2133742C1 (ru) 1999-07-27
NO931638L (no) 1993-11-08
HK98197A (en) 1997-08-08
GR3023421T3 (en) 1997-08-29
PL298828A1 (en) 1993-12-27
HU218938B (hu) 2001-01-29
JP3286391B2 (ja) 2002-05-27
IL105481A0 (en) 1993-08-18
KR100277454B1 (ko) 2001-01-15
NO931638D0 (no) 1993-05-05
ZA932914B (en) 1993-11-12
NO303065B1 (no) 1998-05-25
AU659545B2 (en) 1995-05-18
DE69308229T2 (de) 1997-07-17

Similar Documents

Publication Publication Date Title
ES2100459T3 (es) Derivados de n-isoxazol-fenilsulfonamidas y su uso como antagonistas de la endotelina.
DK0702012T3 (da) Substituerede isoxazolsulfonamider og anvendelse deraf som endothelin-antagonister
ES2103061T3 (es) Derivados de n-isoxazol-naftilsulfonamida y su uso como antagonistas de la endotelina.
ES2074463T3 (es) Compuestos de nitrometileno, su preparacion y su uso como pesticidas.
KR950016517A (ko) 포아 아누아(Poa annua)용 제초 조성물
AP9300580A0 (en) Oxa- and thiadiazole derivatives.
ATE126789T1 (de) Oximinetherderivate.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 569193

Country of ref document: ES